Amgen and Allergan's MVASI ™ (bevacizumab-awwb) and KANJINTI™ (trastuzumab-anns) now available in the United States

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news